A novel optical biosensor format for the detection of clinically relevant TP53 mutations

Simple item page
dc.contributor.authorWilson, P. K.
dc.contributor.authorJiang, T.
dc.contributor.authorMinunni, Maria E.
dc.contributor.authorTurner, Anthony P. F.
dc.contributor.authorMascini, Marco
dc.date.accessioned2009-04-24T18:27:40Z
dc.date.available2009-04-24T18:27:40Z
dc.date.issued2005-05-15
dc.description.abstractThe TP53 gene has been the subject of intense research since the realisation that inactivation of this gene is common to most cancer types. Numerous publications have linked TP53 mutations in general or at specific locations to patient prognosis and therapy response. The findings of many studies using general approaches such as immunohistochemistry or sequencing are contradictory. However, the detection of specific mutations, especially those occurring in the structurally important L2 and L3 zinc binding domains, which are the most common sites of TP53 mutations, have been linked to patient prognosis and more strongly to radiotherapy and chemotherapy resistance in several major cancers. In this study, the TI-SPR-1 surface plasmon resonance system and Texas Instruments Spreeta™ chips were used to develop a DNA biosensor based on thiolated probes complementary to these domains. The sensors were able to detect these mutations in both oligonucleotides and PCR products with normal and mutant TP53 DNA, but the difference in hybridisation signal was small. Preliminary experiments to enhance the signal using Escherichia coli mismatch repair proteins, MutS and single strand binding protein were carried out. It was found that MutS was unable to bind to mismatch oligonucleotides, but single strand binding protein was able to bind to single stranded probes, which had not hybridised to the target, resulting in a three-fold increase in the sensitivity of the biosensor. While further work needs to be carried out to optimise the system, these preliminary experiments indicate that the TI-SPR-1 can be used for the detection of clinically relevant mutations in the TP53 gene and that the sensitivity can be increased significantly using single strand binding protein. This system has a number of advantages over current mutation detection technologies, including lower cost, ease of sensor preparation and measurement procedures, technical simplicity and increased speed due to the lack of need for gel electrophoresis.en_UK
dc.identifier.citationP.K. Wilson, T. Jiang, M.E. Minunni, A.P.F. Turner, M. Mascini, A novel optical biosensor format for the detection of clinically relevant TP53 mutations, Biosensors and Bioelectronics, Volume 20, Issue 11, 15 May 2005, Pages 2310-2313en_UK
dc.identifier.issn0956-5663
dc.identifier.urihttp://dx.doi.org/10.1016/j.bios.2004.11.020
dc.identifier.urihttp://hdl.handle.net/1826/3350
dc.language.isoenen_UK
dc.publisherElsevieren_UK
dc.subjectTP53 mutationen_UK
dc.subjectp53 Mutationen_UK
dc.subjectDNA biosensoren_UK
dc.subjectSurface plasmon resonanceen_UK
dc.subjectMutation detectionen_UK
dc.subjectOptical biosensoren_UK
dc.titleA novel optical biosensor format for the detection of clinically relevant TP53 mutationsen_UK
dc.typePostprinten_UK

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
A novel optical biosensor format for the detection of clinically relevant TP53 mutations -2005.pdf
Size:
64.95 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.89 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Staff publications - Cranfield Health